Congress spotlights J&J stent ops

Who's the drug watchdog's watchdog? Congress, of course--and it's barking at the FDA and Johnson & Johnson. Late yesterday, the House Committee on Energy and Commerce asked for more information about contamination problems the drug agency found in 2004 at J&J's Cordis unit, which makes a drug-coated stent called Cypher. The FDA sent a letter to Cordis at the time, notifying the company of "systemic violations" that caused the stents to be adulterated during the manufacturing process.

Now, the committee wants to know why J&J was allowed to continue selling the Cypher stents--and it plans to dig through emails, notes, reports, and the like, plus interview people at the FDA and J&J.

- read the report from The Wall Street Journal (sub. req.)

Related Articles:
Medical device makers to fund stent safety study. Report
Stent study surprises. Report
Decline in drug-coated stent use at cardiac centers. Report
Insurers may cut stent payouts. Report

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

Vaccine maker Inovio has accused a longtime manufacturing partner of hampering its efforts to produce 1 million doses of a potential COVID-19 vaccine.